News
Gilead’s twice-yearly HIV PrEP 100% effective, says study
Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in pr
